Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598906 | 0.90 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1ALDH1A1HRH3KDM4E | |
| SCHEMBL302125 | 0.88 | L3MBTL1 (0.38) | L3MBTL3L3MBTL1ALDH1A1HRH3KDM4E | |
| SCHEMBL3585321 | 0.83 | KDM4E (0.33) | L3MBTL3L3MBTL1ALDH1A1KDM4ETDP1 | |
| SCHEMBL14371441 | 0.83 | KDM4E (0.36) | L3MBTL3L3MBTL1ALDH1A1KDM4ETDP1 | |
| SCHEMBL738309 | 0.78 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1 | |
| SCHEMBL735577 | 0.76 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL737518 | 0.76 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL737566 | 0.76 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1KDM4E | |
| SCHEMBL81624 | 0.75 | L3MBTL1 (0.39) | L3MBTL3L3MBTL1ALDH1A1HRH3KDM4E | |
| SCHEMBL738620 | 0.73 | SMN1; SMN2 (0.42) | L3MBTL3L3MBTL1ALDH1A1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101516888-A | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | L3MBTL3 2360/4885L3MBTL1 1749/4885ALDH1A1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.